MacroGenics Inc
MGNX1.645USD
+0.065+4.11%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
103.78MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über MacroGenics Inc Unternehmen
MacroGenics, Inc. is a biopharmaceutical company focused on developing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. It generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is developing product candidates that target various tumor-associated antigens and immune checkpoint molecules. Its lead pipeline program is vobramitamab duocarmazine (vobra duo), an antibody-drug conjugate (ADC) that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. Its clinical pipeline includes two product candidates based on its, bispecific DART technology that co-engages both PD-1 and other checkpoint molecules. These candidates include lorigerlimab and tebotelimab. In addition, it is developing MGD024, a bispecific DART molecule. It is also developing various other programs.
Unternehmensinformationen
BörsenkürzelMGNX
Name des UnternehmensMacroGenics Inc
IPO-datumOct 10, 2013
CEODr. Scott Koenig, M.D., Ph.D.
Anzahl der mitarbeiter341
WertpapierartOrdinary Share
GeschäftsjahresendeOct 10
Addresse9704 Medical Center Drive
StadtROCKVILLE
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl20850
Telefon13012515172
Websitehttps://www.macrogenics.com/
BörsenkürzelMGNX
IPO-datumOct 10, 2013
CEODr. Scott Koenig, M.D., Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Scott Koenig, M.D., Ph.D.
Dr. Scott Koenig, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.37M
+45.23%
Mr. James Karrels
Mr. James Karrels
Chief Financial Officer, Senior Vice President, Corporate Secretary
Chief Financial Officer, Senior Vice President, Corporate Secretary
186.80K
--
Mr. Edward (Ed) Hurwitz, J.D.
Mr. Edward (Ed) Hurwitz, J.D.
Independent Director
Independent Director
44.07K
+17.30%
Dr. Stephen L. Eck, M.D., Ph.D.
Dr. Stephen L. Eck, M.D., Ph.D.
Senior Vice President - Clinical Development, Chief Medical Officer
Senior Vice President - Clinical Development, Chief Medical Officer
29.38K
--
Mr. Thomas Spitznagel, Ph.D.
Mr. Thomas Spitznagel, Ph.D.
Senior Vice President - Technical Operations
Senior Vice President - Technical Operations
21.40K
+157.36%
Mr. William K. Heiden
Mr. William K. Heiden
Independent Chairman of the Board
Independent Chairman of the Board
11.00K
+144.44%
Dr. Margaret A. Liu, M.D.
Dr. Margaret A. Liu, M.D.
Independent Director
Independent Director
11.00K
+144.44%
Dr. Ezio Bonvini, M.D.
Dr. Ezio Bonvini, M.D.
Senior Vice President - Research, Chief Scientific Officer
Senior Vice President - Research, Chief Scientific Officer
--
--
Mr. Scott T. Jackson
Mr. Scott T. Jackson
Independent Director
Independent Director
--
--
Mr. Eric Risser
Mr. Eric Risser
Chief Operating Officer
Chief Operating Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Scott Koenig, M.D., Ph.D.
Dr. Scott Koenig, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.37M
+45.23%
Mr. James Karrels
Mr. James Karrels
Chief Financial Officer, Senior Vice President, Corporate Secretary
Chief Financial Officer, Senior Vice President, Corporate Secretary
186.80K
--
Mr. Edward (Ed) Hurwitz, J.D.
Mr. Edward (Ed) Hurwitz, J.D.
Independent Director
Independent Director
44.07K
+17.30%
Dr. Stephen L. Eck, M.D., Ph.D.
Dr. Stephen L. Eck, M.D., Ph.D.
Senior Vice President - Clinical Development, Chief Medical Officer
Senior Vice President - Clinical Development, Chief Medical Officer
29.38K
--
Mr. Thomas Spitznagel, Ph.D.
Mr. Thomas Spitznagel, Ph.D.
Senior Vice President - Technical Operations
Senior Vice President - Technical Operations
21.40K
+157.36%
Mr. William K. Heiden
Mr. William K. Heiden
Independent Chairman of the Board
Independent Chairman of the Board
11.00K
+144.44%
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Wed, Jul 9
Aktualisiert: Wed, Jul 9
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Bellevue Asset Management AG
15.74%
Armistice Capital LLC
9.98%
BlackRock Institutional Trust Company, N.A.
7.13%
The Vanguard Group, Inc.
7.02%
Wasatch Global Investors Inc
5.15%
Other
54.98%
Aktionäre
Aktionäre
Anteil
Bellevue Asset Management AG
15.74%
Armistice Capital LLC
9.98%
BlackRock Institutional Trust Company, N.A.
7.13%
The Vanguard Group, Inc.
7.02%
Wasatch Global Investors Inc
5.15%
Other
54.98%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
35.01%
Investment Advisor/Hedge Fund
21.21%
Hedge Fund
20.14%
Private Equity
5.03%
Individual Investor
3.10%
Research Firm
2.87%
Pension Fund
0.53%
Bank and Trust
0.10%
Family Office
0.02%
Other
12.00%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
350
55.50M
87.97%
-21.64M
2025Q1
365
56.04M
88.82%
-21.64M
2024Q4
367
57.72M
91.98%
-20.16M
2024Q3
367
57.51M
91.64%
-21.39M
2024Q2
370
63.01M
100.47%
-16.59M
2024Q1
368
67.02M
107.12%
-8.36M
2023Q4
353
64.08M
103.25%
-12.72M
2023Q3
352
60.31M
97.24%
-15.19M
2023Q2
356
62.23M
100.48%
-18.91M
2023Q1
389
60.87M
98.46%
-22.53M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Bellevue Asset Management AG
9.93M
15.74%
--
--
Jun 01, 2025
Armistice Capital LLC
6.30M
9.98%
+20.00K
+0.32%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.50M
7.13%
-147.34K
-3.17%
Mar 31, 2025
The Vanguard Group, Inc.
4.43M
7.02%
+109.31K
+2.53%
Mar 31, 2025
Wasatch Global Investors Inc
3.25M
5.15%
-238.25K
-6.83%
Mar 31, 2025
Frazier Life Sciences Management, L.P.
3.18M
5.03%
--
--
Mar 31, 2025
Acadian Asset Management LLC
2.31M
3.66%
+1.02M
+78.84%
Mar 31, 2025
Millennium Management LLC
1.72M
2.73%
-1.14M
-39.81%
Mar 31, 2025
Two Sigma Investments, LP
1.72M
2.73%
-256.25K
-12.95%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.46M
2.31%
+22.97K
+1.60%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
iShares Micro-Cap ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.01%
iShares Biotechnology ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
Vanguard US Momentum Factor ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
SPDR S&P Biotech ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
iShares Genomics Immunology and Healthcare ETF
0%
Mehr Anzeigen
iShares Micro-Cap ETF
Anteil0.02%
ProShares Ultra Nasdaq Biotechnology
Anteil0.01%
iShares Biotechnology ETF
Anteil0.01%
Invesco Nasdaq Biotechnology ETF
Anteil0.01%
Vanguard US Momentum Factor ETF
Anteil0%
DFA Dimensional US Core Equity Market ETF
Anteil0%
Fidelity Nasdaq Composite Index ETF
Anteil0%
SPDR S&P Biotech ETF
Anteil0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Anteil0%
iShares Genomics Immunology and Healthcare ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
